Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11134877 | 0.91 | S1PR1 (0.58) | ALDH1A1FFAR1SLC5A1SLC5A2HPGD | |
| Benzylacetone SCHEMBL27625519 | 0.90 | ALDH1A1 (0.81) | ALDH1A1FFAR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL10912165 | 0.89 | ALDH1A1 (0.77) | ALDH1A1FFAR1MAOAKDM4ENPC1 | |
| SCHEMBL11543795 | 0.88 | LMNA (0.53) | ALDH1A1FFAR1SLC5A1SLC5A2HPGD | |
| SCHEMBL11536859 | 0.86 | NAAA (0.50) | ALDH1A1FFAR1HPGDLMNAMAPT | |
| SCHEMBL11243506 | 0.85 | FFAR1 (0.57) | ALDH1A1FFAR1KDM4ELMNAMAPT | |
| SCHEMBL9627732 | 0.85 | MAOB (0.68) | FFAR1MAOAMAOB | |
| SCHEMBL11638377 | 0.84 | FAAH (0.50) | ALDH1A1FFAR1HPGDLMNAMAPT | |
| SCHEMBL16638504 | 0.83 | ALDH1A1 (0.63) | ALDH1A1FFAR1MAOAKDM4ENPC1 | |
| SCHEMBL9253136 | 0.82 | TAAR1 (0.50) | FFAR1SLC5A1SLC5A2HPGDMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808411-B | Notebook computer shell and injection molding process thereof | 安徽英力电子科技股份有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-111808411-A | Notebook computer shell and injection molding process thereof | 合肥佐佑信息技术有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-105384707-B | A kind of preparation method of α amino acetophenones light trigger | 山东久日化学科技有限公司 | 2018-04-17 | — | — | CN | claimed |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260053748-A1 | NOVEL METHODS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-3768271-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12533355-B2 | Methods of treatment comprising administering lumateperone mono-tosylate capsules | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12521410-B2 | Compounds and pharmaceutical uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2026-01-13 | — | — | US | disclosed |
| US-12496300-B2 | Methods of treating acute depression and anxiety | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250352469-A1 | NOVEL COMPOSITIONS, DEVICES, AND METHODS | INTRA CELLULAR THERAPIES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2006089038-A2 | INSECTICIDAL TETRAHYDROINDENOPYRIDINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
| CN-1209125-A | Piperazine derivatives as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-02-24 | — | — | CN | disclosed |
| EP-0306440-A2 | 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
| US-4140713-A | Phenylethanolamine therapeutic agents | ALLEN & HANBURYS LIMITED (GB) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533355-B2 | Methods of treatment comprising administering lumateperone mono-tosylate capsules | HTR2C, SLC6A4, SLC6A2 | ALDH1A1 1128/4885FFAR1 336/4885SLC5A1 77/4885 |
| US-20250352469-A1 | NOVEL COMPOSITIONS, DEVICES, AND METHODS | LIPA, DHCR7, HSD17B7 | ALDH1A1 2752/4885FFAR1 284/4885SLC5A1 294/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | ALDH1A1 2077/4885FFAR1 183/4885SLC5A1 999/4885 |
| US-20260053748-A1 | NOVEL METHODS | HTR1D, HTR2C, HTR1A | ALDH1A1 529/4885FFAR1 490/4885SLC5A1 850/4885 |
| US-12496300-B2 | Methods of treating acute depression and anxiety | HTR2A, HTR1A, HTR3B | ALDH1A1 1650/4885FFAR1 631/4885SLC5A1 3320/4885 |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | HTR2C, DRD2, HTR2A | ALDH1A1 669/4885FFAR1 81/4885SLC5A1 756/4885 |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | HTR2A, HTR2C, HTR5A | ALDH1A1 436/4885FFAR1 152/4885SLC5A1 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.